C(60) Fullerene as Synergistic Agent in Tumor-Inhibitory Doxorubicin Treatment

BACKGROUND: Doxorubicin (Dox) is one of the most potent anticancer drugs, but its successful use is hampered by high toxicity caused mainly by generation of reactive oxygen species. One approach to protect against Dox-dependent chemical insult is combined use of the cytostatic drug with antioxidants...

Descripción completa

Detalles Bibliográficos
Autores principales: Prylutska, Svitlana, Grynyuk, Iryna, Matyshevska, Olga, Prylutskyy, Yuriy, Evstigneev, Maxim, Scharff, Peter, Ritter, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269825/
https://www.ncbi.nlm.nih.gov/pubmed/25504158
http://dx.doi.org/10.1007/s40268-014-0074-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269825/
https://www.ncbi.nlm.nih.gov/pubmed/25504158
http://dx.doi.org/10.1007/s40268-014-0074-4

Ejemplares similares